We compared quantitative reverse transcriptase polymerase chain reaction (Q-RT-PCR) to qualitative RT-PCR in determining response to therapy and predicting clinical outcome in 18 retrospectively selected patients with ALL positive for the ALL1-AF4 fusion and with frozen RNA samples collected at diagnosis and during follow-up (96 samples analysed). The ALL1-AF4 junction was detected by qualitative RT-PCR in 18 patients and by Q-RT-PCR in 17 patients (one patient harboured the rare e10-e6 ALL1-AF4 junction, which falls outside of the primer and probe location designed for the Q-RT-PCR). In three of the 12 patients negative to qualitative RT-PCR after induction therapy, a small number of ALL1-AF4 copies was detected by Q-RT-PCR. Thus nine patients were negative and eight positive. Seven of the eight positive patients suffered a relapse, including two of the three patients positive to Q-RT-PCR yet negative to qualitative RT-PCR. Moreover, we found two (5%) discordant results among the 39 follow-up tests of the nine patients who converted to a negative qualitative-quantitative PCR status. The results suggest that qualitative RT-PCR is more appropriate for the routine diagnosis of this genetic alteration. However, Q-RT-PCR is more accurate in assessing the molecular response after induction treatment and could be more useful in clinical decision-making in ALL1-AF4-positive ALL patients.
Introduction
The quantitative reverse transcriptase polymerase chain reaction (Q-RT-PCR) detects the number of fusion-transcript copies in acute leukaemia cells and may be more accurate than qualitative RT-PCR. In fact, it allows the target RNA values to be normalized through the amplification of a housekeeping gene and the simultaneous construction of a calibrator standard curve. Q-RT-PCR may also reduce the potential carryover of contaminating cDNAs because it is performed in a closed-tube system. However, with respect to qualitative RT-PCR, Q-RT-PCR requires more sophisticated instruments, as well as reagents that degrade easily and are expansive. 1, 2 Several recent studies have compared qualitative and quantitative RT-PCR for monitoring minimal residual disease (MRD) in patients with acute myeloid leukaemia (AML) or acute lymphoid leukaemia (ALL) expressing the fusion transcripts BCR/ ABL, CBFbeta/MYH11, or AML1-ETO, and the results have shown that Q-RT-PCR may provide better prognostic indicators. [3] [4] [5] [6] [7] [8] These findings may be explained by the notion that the leukaemic clones that carry the above-mentioned fusion transcripts are cleared slowly, or not completely, by the currently used forms of antileukaemic treatment. Thus knowledge of the kinetics of the clearance of these fusion transcripts could be more clinically useful than their simple detection. However, it has not been firmly established whether or not Q-RT-PCR provides better prognostic indicators than qualitative RT-PCR in patients with acute leukaemia who respond rapidly to chemotherapy, converting to a negative PCR status, such as patients with acute promyelocytic leukaemia (APL) 9, 10 or ALL1-AF4-positive ALL. 11 The objective of the present study was to compare retrospectively qualitative and quantitative RT-PCR in the diagnosis and monitoring of the ALL1-AF4 chimeric gene, in order to evaluate the capacity of these methods to determine the response to therapy and to predict clinical outcome.
Materials and methods
The study population consisted of 18 retrospectively selected patients who were diagnosed with ALL1-AF4-positive ALL in the period from 1998 to 2002 and for whom frozen RNA samples collected at diagnosis and during clinical follow-up were available. The diagnosis of ALL was based on standard morphocytochemical and immunophenotypic criteria. In all, 16 patients were adults and two were infants. The adults had been enrolled in three different Italian Muticentric GIMEMA studies, which had been open to enrolment at the time the patients were diagnosed. The two infants were diagnosed and treated at the Haematology Unit of the 'Bambino Gesù' Paediatric Hospital, Vatican City.
The GIMEMA studies for the treatment of ALL include a centralized programme of cell sample handling at diagnosis and during the clinical follow-up of patients. According to this programme, the diagnostic molecular and cytogenetic analyses were performed in the reference laboratories of the Department of Cellular Biotechnology and Haematology of the University 'La Sapienza' (Rome); the Department of Clinical and Biological Science of the 'San Luigi Gonzaga' Hospital of the University of Turin (Orbassano); the Department of Haematology of the University of Perugia; and the Heamatology Unit of the Department of Biomedical Sciences, University of Ferrara. In all cases, the Q-RT-PCR molecular monitoring of MRD was assessed exclusively at the laboratory of the Department of Clinical and Biological Science of the 'San Luigi Gonzaga' Hospital of the University of Turin (Orbassano). Mononuclear cells were obtained from bone marrow samples after centrifugation on a Ficoll-Hypaque gradient; they were washed and cryopreserved in 4 M guanidium isothiocyanate at À201C until used for total RNA extraction, or as dry pellet for DNA extraction. All patients had a genomic rearrangement of the ALL1 locus, which resulted in the ALL1-AF4 fusion transcript. All patients carried the t(4;11) abnormality at the karyotype.
Treatment
The adult patients were treated according to the GIMEMA studies for adult ALL. In particular, one patient was treated following the GIMEMA 0288 regimen, 12 eight patients according to the GIMEMA 0496 regimen, 13 and six patients according to the GIMEMA ALL 2000 regimen. The latter study is currently open to enrolment and considers ALL1-AF4-positive ALL patients as having a negative prognosis; these patients thus undergo an intensified consolidation phase with high-dose Ara-C and mithoxantrone (HAM), followed by either allogeneic or autologous haemopoietic stem cell transplantation, depending on the availability of an HLA-identical donor. The two infants were treated according to the pilot protocol of either AIEOP 9503 14 or INTERFANT 99. The latter protocol includes both low-and high-dose cytarabine and other anti-AML agents that are also active against ALL, administered following an AML-like schedule.
Cytogenetic analysis
Cytogenetic analysis was performed on bone marrow cells after 24 h of unstimulated culture. GTG bands with trypsin were obtained. Karyotypes were reviewed and defined according to the criteria of the International System for Human Cytogenetic Nomenclature. 15 
RNA isolation and cDNA synthesis
Total RNA was extracted from cells cryopreserved in guanidium isothiocyanate according to the method of Chomczynsky and Sacchi. 16 The quality of RNA was assessed on an ethidium bromide-stained 1% agarose gel containing 2.2 mol/l formaldehyde. In vitro reverse transcription of 1 mg of total RNA to cDNA was performed in a final volume of 20 ml, with a final concentration of 2.5 mM of random examers, 1 mM of each dNTP, 5 mM MgCL 2 solution, 1 Â PCR buffer, 1 U/ml RNAase inhibitor, and cloned Moloney-murine leukaemia virus (Mo-MLV) reverse transcriptase used at a concentration of 2.5 U/ml for qualitative RT-PCR and a concentration of 50 U/ml for Q-RT-PCR. The reaction parameters were 20 min at 421C in both cases.
Qualitative nested RT-PCR
Qualitative amplification of the ALL1-AF4 fusion product was performed according to the method described by Biondi et al.
17
In brief, a volume of 5 ml of retrotranscribed cDNA was diluted with 95 ml of a PCR mixture containing 1.5 mM/l MgCl 2 , 50 mM/l KCl, 10 mM/l Tris-HCl pH 8.3, 200 mM/l of each dNTP, 2.5 U/ml Taq DNA polymerase (Applied Biosystems), and 15 pM of the EX5 and AF4.1 primers. After an initial denaturation at 941C for 2 min, 30 cycles of amplification were performed on a 2400 DNA Thermal Cycler (Applied Biosystems). One cycle of denaturation, annealing, and extension consisted of, respectively, 941C for 1 min, 561C for 1 min, and 721C for 1 min. Upon completion, 1 ml of the initial PCR product was used for a second round of PCR amplification for an additional 30 cycles, using the primers EX6 and AF4.1 (half-nested PCR). Finally, for the qualitative analysis of the amplification product, 1/10 of the product was run on a 2% agarose gel stained with ethidium bromide and visualized under a UV lamp. The primer sequences used were as folows: forward primer EX5, 5 0 -GAG GAT CCT GCC CCA AAG AAA AG-3 0 ; reverse EX6 primer: 5 0 -CGC CCA AGT ATC CCT GTA AAA C-3 0 ; and reverse primer AF4.1, 5 0 -TGA GCT GAA GCT GGT CTT CGA GC-3 0 . Amplification of the normal ALL1 gene mRNA was performed with the same cDNA preparation and with the same conditions used to identify the ALL1-AF4 fusion product, with the following primers: forward primer EX6, 5 0 -CGC CCA AGT ATC CCT GTA AAA C-3 0 ; and reverse primer EX7, 5 0 -CTT AAA GTC CAC TCT GAT CCT-3 0 . Negative controls (ie reagents and water) were included in all PCR experiments. To rule out the possibility that the RNA samples were contaminated with cDNA, all tests with positive results were repeated, mixing all reagents without RNA. As previously reported, serial dilution experiments established that our RT-PCR assay allowed one ALL1-AF4-positive cell in a background of 10 4 normal cells to be detected. Dilution experiments showing the same level of sensitivity have been serially performed. 18 
Q-RT-PCR
The number of ALL1-AF4 copies was determined according to the methods developed by the European Concerted Action of the Europe Against Cancer (EAC) Program. 19 All of the Q-RT-PCR reactions were performed on a 7700 ABI platform (Applied Biosystems). To amplify the vast majority of ALL1-AF4 fusions, two Q-RT-PCR sets were used with a common probe (ENP 242) and a common reverse primer on AF4 EX5 (ENR 262). The first set used a forward primer on ALL1 EX9 (ENF 207) and the second set used a forward primer on ALL1 EX10 (ENF 208). PCR primers and probes were designed using the Primer Express software program. The number of amplification cycles was fixed at 50. Moreover, a common threshold set at 0.1 was selected in order to remain within the exponential phase. In determining the integrity of RNA, the criteria for excluding RNA samples were established as an ABL cycle threshold (Ct) value higher than the normal range of 22-29.3 . The number of fusion transcripts obtained was normalized with respect to the number of ABL transcripts and expressed as the number of ALL1-AF4 copies per 10 4 copies of ABL (ALL1-AF4/ABL Â 10 4 ). 20 All experiments were carried out in duplicate with appropriate negative controls and a control that included a mixture of all reagents without RNA, to rule out the possibility of cDNA contamination of RNA samples.
A dilution of a series of plasmids was used to generate standard ALL1-AF4 and ABL curves. In particular, three different fusion gene reagent sets (Ipsogen Cancer Profiler), carrying the e9-e5, e10-e4, and e11-e5 ALL1-AF4 junctions, respectively, were used to generate the standard ALL1-AF4 curves In brief, the two PCR reactions performed to amplify the ALL1-AF4 fusions included 5 ml of template in 25 ml reaction mixture containing 12.5 ml of universal master mix (Applied Biosystems), 300 nM of the forward primer ENF 207 (5 0 -CCC AAG TAT CCC TGT AAA ACA AAA A-3 0 ) for the first PCR reaction and 300 nM of the forward primer ENF 208 (5 0 -GAT GGA GTC CAC AGG ATC AGA GT-3 0 ) for the second reaction, and 300 nM of the reverse primer ENR 262 (5 0 -GAA AGG AAA CTT GGA TGG CTC A-3 0 ). For both of the PCR reaction mixtures, we used 200 nM of the same breakpoint specific probe ENP 242 (5 0 -CAT GGC CGC CTC CTT TGG CAG C-3 0 ) labelled with FAM reporter at the 5 0 end and TAMRA quencher at the 3 0 end. The exact primer location within the ALL1-AF4 junction is illustrated in Figure 1 .
To assess the number of copies of the ABL housekeeping gene, we used 300 nM of the ENF 1003 forward primer (5 0 -TGG AGA TAA CAC TCT AAG CAT AAC TAA AGG-3 0 ), 300 nM of the ENR 1063 reverse primer (5 0 -GAT GTA GTT GCT TGG GAC CCA-3 0 ), and 200 nM of the specific probe ENPr 1043 (5 0 -CCA TTT TTG GTT TGG GCT TCA CAC CATT-3 0 ) labelled with FAM reporter at the 5 0 end and TAMRA quencher at the 3 0 end. The Q-RT-PCR reactions were incubated at 501C for 2 min, followed by 10 min at 951C, and were subjected to 50 cycles of Q-RT-PCR amplification. One cycle of denaturation, annealing, and extension consisted of 951C for 15 s, 601C for 30 s, and 601C for 30 s, respectively. Efficiency of our Q-RT-PCR assay was evaluated by calculating the slope values of the plasmid dilution curves that, according to the recommendation of the EAC concerted action, must be close to the theoretical slope value of À3.32. Finally, to determine the sensitivity of our Q-RT-PCR assay, the diagnostic RNA sample from patient no. 1 was serially diluted by mixing with normal BM RNA, reverse transcribed and amplified as previously described in this section. The results of these serial dilution experiments demonstrated that our Q-RT-PCR assay allows detection of one ALL1-AF4-positive cell in a background of 10 6 normal cells. This sensitivity level resulted better than the one observed in our standardized nested RT-PCR method that detected one ALL1-AF4-positive cell in a background of 10 4 .
DNA analysis
High-molecular-weight DNA was obtained from cell pellets after proteinase K digestion and phenol-chloroform extraction, 21 digested to completion with BamHI and BglII, sized, fractionated by electrophoresis with a 0.8% agarose gel, and transferred to nitrocellulose membranes. Filters were prehybridized for 16-24 h at 421C in a solution containing 50% deionized salmon sperm, 5 Â SSC, 5 Â Denhart's solution, and 100 mg of denatured salmon sperm DNA per millilitre, and then hybridized in the same solution with the addition of a denatured B859 probe (a cDNA insert that explores the entire ALL1 breakpoint cluster region 22 ) previously labelled with the phosphorus 32 random priming technique. Filters were washed twice for 30 min in 0.2 Â SSC and 0.1% sodium dodecyl sulphate at 651C and exposed with an intensifying screen at À701C for 24-72 h.
Criteria for defining response to treatment and statistical analyses
Complete haematological remission (CHR) was defined as normal bone marrow cellularity with o5% undifferentiated cells and normalization of peripheral blood counts. Complete molecular remission (CMR) was defined by the absence of the specific ALL1-AF4 amplification band detected at diagnosis by the qualitative RT-PCR and/or the Q-RT-PCR. Qualitative RT-PCR negativity was assessed on ethidium bromide-stained electrophoresis gel, in the presence of RNA integrity, as evaluated by minigel visualization and the successful amplification of the control gene, whereas Q-RT-PCR negativity was defined by a ratio between ALL1-AF4 copies and ABL copies equal to zero (ALL1-AF4 Ct ¼ 50).
The statistical significance of the differences in the mean number of ALL1-AF4 copies was evaluated by the two-tailed Student's t-test. Differences in the distribution of clinical and biological features were analysed by the two-tailed Fisher's exact test for categorical data. The probabilities of haematological relapse and overall survival were estimated with the KaplanMeier method and were compared with the log-rank test.
Results and discussion
The clinical and biological characteristics at diagnosis, the type of treatment, the molecular response, and the clinical outcome of the 18 study patients are shown in Table 1 . Some of the 2, 3, 4, 5, 6, 8, 9 , 17, and 18) have been described elsewhere. 11, 18 In all, 10 patients were males and eight females. Two patients were infants (o1 year of age). A total of 96 RNA samples were analysed, with an average number of 5.6 tests per patient (range 3-13) and a follow-up ranging from 4 to 62 months.
Qualitative RT-PCR vs quantitative RT-PCR
All patients had an immunophenotypic pro-B ALL (ie TdT þ , HLADR þ , CD19 þ ; CD10À, cyIgÀ; sIgÀ) with t(4;11) cytogenetic alteration and a rearranged ALL1 genomic configuration. The ALL1-AF4 junction was detected by qualitative RT-PCR in 18 (100%) patients and by Q-RT-PCR in 17 patients (94.4%) ( Table 1) . In all these Q-RT-PCR experiments, the slope values of the plasmid dilution curves ranged between À3.00 and À3.50, which are very close to the theoretical value of À3.32. These results showed that, irrespective of the type of ALL1-AF4 junctions, the efficiency of our Q-RT-PCR assay approached 100% in all cases. The nucleotide sequencing of the 289 bp qualitative RT-PCR product, amplified in the one patient who was negative to Q-RT-PCR after induction treatment, showed that this patient harboured the rare e10-e6 ALL1-AF4 junction, which fell outside of the primer and probe location designed for Q-RT-PCR ( Figure 1b) ; 23 thus, in the present study, the two assays were only compared for the 17 patients who were positive according to both qualitative and quantitative RT-PCR. False-negative Q-RT-PCR results may occur when testing chimeric genes that generate a variety of fusion transcripts, such as TEL-AML1 and CBFb-MHY11. 6, 24 To amplify all of the transcripts generated by these chimeric genes, it would be necessary to use a very high number of primer pairs, probes, and amplification reactions, given that the optimal amplicon length for quantitative amplification is less than 100 bp. Thus for the sake of feasibility, when testing these chimeric genes, the Q-RT-PCR is limited to detect only those products generated by the vast majority, and not the totality, of junctions. 25, 26 Since ALL1-AF4 is a chimeric gene generating a variety of fusion transcripts, the EAC Program developed a Q-RT-PCR strategy that was able to detect at least 90% of non-infant and 60% of infant ALL1-AF4-positive ALL cases. 19 Therefore, based on these considerations and on the data obtained in the present study, we believe that qualitative RT-PCR is the most appropriate method for the routine diagnosis of this genetic alteration.
At diagnosis, the mean number of ALL1-AF4 copies (ie ALL1-AF4/ABL Â 10 4 ) in leukaemic cells was 5926 (range 435-22 045). Table 2 shows the mean number of ALL1-AF4 copies 
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at diagnosis, by white blood cell (WBC) count at diagnosis, the achievement of CMR, and the occurrence of haematological relapse. The only statistically significant association was the trend towards an inverse association between the WBC count and the mean number of ALL1-AF4 copies at diagnosis, with a mean of 9259.2 (77826.9) ALL1-AF4 copies for patients with a WBC count of r50 Â 10 9 /l and 4080.9 (74,050.6) copies for those with a count of 450 Â 10 9 /l (P ¼ 0.052). Therefore, we failed to demonstrate any correlation between the number of fusion copies at diagnosis and disease burden or clinical outcome. These findings are similar to the data reported by Gallagher et al 27 in PML/RARalfa leukaemic patients. However, in the setting of PML/RARalfa-, AML1-ETO-or CBFB-MYH11-positive AML, Schnittger et al 28 have recently reported that high levels of fusion gene expression at diagnosis or less than 3 logs of tumour reduction during the first 3-4 months of therapy significantly affected the clinical outcome of patients. Nevertheless, we would like to underline that in the ALL1-positive leukaemia subset there are several in vitro data that seem to contradict the hypothesis of a direct correlation between the amount of chimeric transcripts and the growth of leukaemia. In fact, Lavau et al 29 showed that the experimental immortalization of primary murine bone marrow cells by ALL1-ENL was associated with very low levels of fusion transcripts and proteins, whereas more recently Caslini et al 30 demonstrated that the induction of high levels of the ALL1-AF9 fusion protein in U937 cells led to rapid cell death within 72 h and that extremely low levels of ALL1 fusion proteins were tolerated.
By definition, all 17 patients achieved CHR after induction treatment. For 12 patients, qualitative RT-PCR was negative. However, in three of these 12 patients, the Q-RT-PCR detected the residual presence of a small number of ALL1-AF4 copies (ie two, four, and seven ALL1-AF4 copies). Thus after induction, nine patients were considered as negative, having achieved CMR, and eight as positive. As shown in Figure 2b , seven of the eight PCR-positive patients suffered a relapse, including two of the three patients who were positive to Q-RT-PCR yet negative to qualitative RT-PCR. Regarding the third patient who was positive to Q-RT-PCR yet negative to qualitative RT-PCR at the end of induction treatment, two discordant results were obtained also during clinical follow-up, although at a certain point the patient tested persistently negative to both Q-RT-PCR and qualitative RT-PCR (patient no. 14 in Figure 2b ). The present preliminary observations may suggest that Q-RT-PCR amplification of the ALL1-AF4 fusion gene could be more accurate, reliable, and even more sensitive, as demonstrated by our serial dilution experiments, than qualitative RT-PCR, in assessing the Table 2 Mean number of ALL1-AF4 copies at diagnosis, by WBC count at diagnosis, the achievement of CMR, and occurrence of clinical relapse 
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L Elia et al molecular response after induction treatment. In fact, Q-RT-PCR detected low amounts of residual ALL1-AF4 copies in three patients who had tested negative to qualitative RT-PCR. In addition, although the low number of observations did not allow us to draw any conclusive prognostic indications, it is interesting to note that two of these three patients later suffered a clinical relapse.
The overall results of the MRD monitoring during the clinical follow-up of the 17 patients are shown in Figure 2a and b for the nine patients in CHR and the eight patients with persistence PCR positivity, respectively. With regard to the ALL1-AF4 level at diagnosis, three of these eight patients showed a reduction of o1 log, whereas the remaining five showed a reduction of 43 logs. Moreover, for three of the eight patients who persisted positive after the induction treatment and who suffered a haematological relapse, the number of ALL1-AF4 copies at relapse was slightly lower than that detected at diagnosis or at CHR (patient nos. 2, 7, and 9; Figure 2b ). These latter observations may suggest that other putative functional derangements occurred in the leukaemic cells of these patients, allowing for the expansion of cell clones that are able to proliferate through very low levels of the fusion protein.
In the nine patients who converted to a negative qualitative and quantitative PCR status at CHR, we retrospectively compared 39 tests (mean of 4.3 tests per patient; range 3-9). Concordant results were achieved in 37 (94%) of the 39 tests (30 negative test results and seven positive results). The two discordant results were found for two different patients, who tested negative to the qualitative assay yet positive to the Q-RT-PCR. In one of these patients (patient no. 6 in Figure 2a) , at 44 months from diagnosis, the Q-RT-PCR revealed a slight increase in the number of ALL1-AF4 copies, which during the remainder of the 62-month total follow-up returned to an undetectable level. With regard to the detection of fusion transcripts years after diagnosis (as found for patient no. 6), we observed qualitative RT-PCR positivity at 5 years from diagnosis in an ALL1-AF4-positive ALL patient not included in this study and who is currently in continuous complete remission. A possible explanation for this biological event is that fusion gene-positive cells may represent expanded clones of preleukaemic cells that remain pathologically and clinically silent or covert in the absence of additional genetic hits, as recently hypothesized by Greaves based on the low levels of leukaemic-specific hybrid genes in healthy individuals 31 and the presence of the TEL-AML1 and AML1-ETO leukaemic fusion genes in cord blood from healthy newborns, detected at a frequency that was 100 times greater than the risk of developing the corresponding leukaemia. 32 By contrast, in patient no. 5 (Figure 2a) , the Q-RT-PCR revealed the reappearance of nine ALL1-AF4 copies at 6 months from diagnosis. Although this patient returned to a negative qualitative and quantitative PCR status 1 month later, after the second course of consolidation therapy, he was later found to be positive to both qualitative and quantitative RT-PCR, and he suffered a molecular and haematological relapse at 4 and 8 months, respectively, after the first Q-RT-PCR. Again, these observations seem to confirm that Q-RT-PCR may be more sensitive than qualitative RT-PCR.
Regarding the clinical outcome of the 17 ALL1-AF4-positive ALL patients by CMR status, the rate of relapse was 87% for the eight patients who did not achieve CMR and 44% for the nine patients who achieved CMR (P ¼ 0.06); the actuarial probability of relapse-free survival at 30 months was 12 and 53%, respectively (P ¼ 0.054); and the rate of overall survival at 30 months was 42 and 25%, respectively (P-value not significant).
In conclusion, our present data demonstrate that qualitative RT-PCR is the most appropriate method for the routine diagnosis of the ALL1-AF4 genetic alteration. In addition, as concern the monitoring of MRD, our findings show that Q-RT-PCR may not only be more accurate and reliable than qualitative RT-PCR, but also even more sensitive. Whether these observations would be confirmed in future prospective studies on the measurement of the ALL1-AF4 transcript levels during the patients follow-up, they would greatly contribute to assess the usefulness of Q-RT-PCR for the clinical decision-making in ALL1-AF4-positive ALL patients and they further condone the use of Q-RT-PCR for monitoring MRD in ALL1-AF4-positive ALL patients. Finally, it appears that the quantification of the ALL1-AF4 fusion levels during the different disease phases may contribute to a deeper understanding of the biological mechanisms underlying leukaemogenesis and disease progression.
